- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04300231
Thoracic Epidural Analgesia Versus Rectus Sheath Block Versus Surgeon Infiltration With Liposomal Bupivacaine or Standard Bupivacaine for Post-Operative Pain Control After Cystectomy
Study Overview
Status
Conditions
Detailed Description
The purpose of this study is to compare the difference between four different pain control methods in patients who will be having a cystectomy surgery (surgical removal of the bladder). By collecting this data, we aim to show improved postoperative pain scores, decreased opioid needs, and decreased opioid side effects (feeling sick to your stomach, feeling drowsy/sleepy, blockage/lack of movement in the intestines, inability to completely empty the bladder, unusually slow or shallow breathing).
The specific aim of this study is to compare the difference between the pain control methods in achieving the following:
- Decreased opioid requirements
- Improved postoperative VAS pain scores
- Decreased opioid side effects (Nausea, sedation, ileus, respiratory depression)
- Decreased hospital length of stay (LOS)
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana Univeristy
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients undergoing cystectomy for bladder cancer
- ASA class 1, 2, 3 or 4
- Age 18 or older, male or female
- Desires Regional anesthesia for postoperative pain control
Exclusion Criteria:
- Any contraindication for thoracic epidural.
- History of substance abuse in the past 6 months.
- Patients on more than 30mg morphine equivalents of opioids daily.
- Any physical, mental or medical conditions which in the opinion of the investigators, may confound quantifying postoperative pain resulting from surgery.
- Known allergy or other contraindications to the study medications (Acetaminophen, Gabapentin, Bupivacaine, Hydromorphone).
- Postoperative intubation.
- Any patient with history of neuropathic bowel or bladder dysfunction
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Thoracic epidural
1. Thoracic epidural- epidural bupivacaine 0.05%/hydromorphone 0.05mg/ml mix will be given throughout the duration of their epidural analgesia.
|
Mix of epidural bupivacaine 0.05% and hydromorphone 0.05mg/ml will be given using PCEA.
Mix of epidural bupivacaine 0.05% and hydromorphone 0.05mg/ml will be given using PCEA.
|
Active Comparator: Rectus Sheath Block
2. Rectus Sheath Block - 20 mL of Exparel® diluted with 40 mL of 0.125% bupivacaine and 40 ml of injectable saline for a total of 100 mL.
The 100 mL will be injected into 4 locations below the rectus abdominis muscle.
|
20 ml
40 mL
40 mL
|
Active Comparator: Surgeon Infiltration with Liposomal Bupivacaine (LB)
3. Surgeon infiltration with Liposomal Bupivacaine (LB) - 20 mL of Exparel® diluted with 40 mL of 0.125% bupivacaine and 40 ml of injectable saline for a total of 100 mL.
The 100 mL will be injected throughout the incision site by the surgeon at the end of surgery, prior to abdominal wall closure.
|
20 ml
40 mL
40 mL
|
Active Comparator: Surgeon Infiltration
4. Surgeon infiltration with Standard Bupivacaine (SB) - 60ml of 0.25% bupivacaine will be diluted with 40ml of saline for a total of 100ml.
The 100 mL will be injected throughout the incision site by the surgeon at the end of surgery.
|
40 mL
60 mL
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
VAS score at 48 hour
Time Frame: Pain scores will be measured 48 hours after surgery
|
The VAS score will be taken with both rest and movement (knee flexion) and will be measured by a study team investigator using Visual Analog Scale (VAS).
Using a scale of 0-10 for documentation with 10 being the worst pain and 0 being no pain
|
Pain scores will be measured 48 hours after surgery
|
VAS score at 72 hour
Time Frame: Pain scores will be measured 72 hours after surgery
|
The VAS score will be taken with both rest and movement (knee flexion) and will be measured by a study team investigator using Visual Analog Scale (VAS).
Using a scale of 0-10 for documentation with 10 being the worst pain and 0 being no pain
|
Pain scores will be measured 72 hours after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Secondary endpoint includes total opioid consumption at 1 hour
Time Frame: Opioid comsumption will be measured at 1 hour
|
Opioid consumption will be collected by a study team member post operatively at hour 1 per protocol time requirements
|
Opioid comsumption will be measured at 1 hour
|
Secondary endpoint includes total opioid consumption at 24 hours
Time Frame: Opioid comsumption will be measured at 24 hours
|
Opioid consumption will be collected by a study team member post operatively at hour 24 per protocol time requirements
|
Opioid comsumption will be measured at 24 hours
|
Secondary endpoint includes total opioid consumption at 48 hours
Time Frame: Opioid comsumption will be measured at 48 hours
|
Opioid consumption will be collected by a study team member post operatively at hour 48 per protocol time requirements
|
Opioid comsumption will be measured at 48 hours
|
Secondary endpoint includes total opioid consumption at 72 hours
Time Frame: Opioid comsumption will be measured at 72 hours
|
Opioid consumption will be collected by a study team member post operatively at hour 72 per protocol time requirements
|
Opioid comsumption will be measured at 72 hours
|
Secondary endpoint includes total opioid consumption at 96 hours
Time Frame: Opioid comsumption will be measured at 96 hours
|
Opioid consumption will be collected by a study team member post operatively at hour 96 per protocol time requirements
|
Opioid comsumption will be measured at 96 hours
|
VAS score at 1 hour
Time Frame: Pain scores will be measured 1 hour after surgery
|
The VAS score will be taken with both rest and movement (knee flexion) and will be measured by a study team investigator using Visual Analog Scale (VAS).
Using a scale of 0-10 for documentation with 10 being the worst pain and 0 being no pain
|
Pain scores will be measured 1 hour after surgery
|
VAS score at 24
Time Frame: Pain scores will be measured 24 hours after surgery
|
The VAS score will be taken with both rest and movement (knee flexion) and will be measured by a study team investigator using Visual Analog Scale (VAS).
Using a scale of 0-10 for documentation with 10 being the worst pain and 0 being no pain
|
Pain scores will be measured 24 hours after surgery
|
VAS score at 96 hour
Time Frame: Pain scores will be measured 96 hours after surgery
|
The VAS score will be taken with both rest and movement (knee flexion) and will be measured by a study team investigator using Visual Analog Scale (VAS).
Using a scale of 0-10 for documentation with 10 being the worst pain and 0 being no pain
|
Pain scores will be measured 96 hours after surgery
|
Average Nausea score 1 hour
Time Frame: 1 hour
|
Nausea scores will be collected by study team member post operatively at hour 1 per protocol.
Nausea will be recorded as none, mild, moderate or severe.
Scoring system being (none=0, mild=1, moderate=2 and severe=3).
|
1 hour
|
Average Nausea score 24 hour
Time Frame: 24 hour
|
Nausea scores will be collected by study team member post operatively at hour 24 per protocol.
Nausea will be recorded as none, mild, moderate or severe.
Scoring system being (none=0, mild=1, moderate=2 and severe=3).
|
24 hour
|
Average Nausea score 48 hour
Time Frame: 48 hour
|
Nausea scores will be collected by study team member post operatively at hour 48 per protocol.
Nausea will be recorded as none, mild, moderate or severe.
Scoring system being (none=0, mild=1, moderate=2 and severe=3).
|
48 hour
|
Average Nausea score 72 hour
Time Frame: 72 hour
|
Nausea scores will be collected by study team member post operatively at hour 72 per protocol.
Nausea will be recorded as none, mild, moderate or severe.
Scoring system being (none=0, mild=1, moderate=2 and severe=3).
|
72 hour
|
Average Nausea score 96 hour
Time Frame: 96 hour
|
Nausea scores will be collected by study team member post operatively at hour 96 per protocol.
Nausea will be recorded as none, mild, moderate or severe.
Scoring system being (none=0, mild=1, moderate=2 and severe=3).
|
96 hour
|
Average Sedation score at 1 hour
Time Frame: 1 hour
|
Sedation scores will be collected by a study team member post operatively at hour 1 per protocol requirements.
Determining if patient is awake & alert=0, quietly awake=1, asleep and arousable=2 or deep sleep=3.
The higher the scores mean a worse outcome.
|
1 hour
|
Average Sedation score at 24 hour
Time Frame: 24 hour
|
Sedation scores will be collected by a study team member post operatively at hour 24 per protocol requirements.
Determining if patient is awake & alert=0, quietly awake=1, asleep and arousable=2 or deep sleep=3.
The higher the scores mean a worse outcome.
|
24 hour
|
Average Sedation score at 48 hour
Time Frame: 48 hour
|
Sedation scores will be collected by a study team member post operatively at hour 48 per protocol requirements.
Determining if patient is awake & alert=0, quietly awake=1, asleep and arousable=2 or deep sleep=3.
The higher scores mean a worse outcome.
|
48 hour
|
Average Sedation score at 72 hour
Time Frame: 72 hour
|
Sedation scores will be collected by a study team member post operatively at hour 72 per protocol requirements.
Determining if patient is awake & alert=0, quietly awake=1, asleep and arousable=2 or deep sleep=3.
The higher the scores mean a worse outcome.
|
72 hour
|
Average Sedation score at 96 hour
Time Frame: 96 hour
|
Sedation scores will be collected by a study team member post operatively at hour 96 per protocol requirements.
Determining if patient is awake & alert=0, quietly awake=1, asleep and arousable=2 or deep sleep=3.
The higher the scores mean a worse outcome.
|
96 hour
|
First Flatus-bowel movement
Time Frame: Assess daily until patient passes gas postoperatively within 72 hours
|
The passing of gas will be collected by a study team member as per protocol requirements.
This is only for the first time the patients passes gas post operatively and is expected to occur during the hospital admission prior to patients discharge.
The outcome measure will be assessed through study completion, an average of 1week.
|
Assess daily until patient passes gas postoperatively within 72 hours
|
Incidence of Urinary Retention-Postoperative Creatinine
Time Frame: Creatinine level will be collected daily postoperatively for 4 days
|
Lab level of Creatinine will be collected if only ordered by the surgeon doing the surgery.
I will be recorded or documented for 4 days post operatively.
|
Creatinine level will be collected daily postoperatively for 4 days
|
Time to Discharge-Length of Stay
Time Frame: From hospital admission to discharge date up to 3weeks
|
LOS will be collected via EMR
|
From hospital admission to discharge date up to 3weeks
|
Incidence of Hypotension
Time Frame: daily during 96 hour assessment period
|
Defined as BP decrease of more than 20% from baseline
|
daily during 96 hour assessment period
|
Incidence of Respiratory Depression
Time Frame: assess daily as yes/no
|
Define by use of Narcan
|
assess daily as yes/no
|
Ambulation Activity
Time Frame: will be recorded daily as yes/no
|
Define as anytime out of bed: up in chair, to bathroom or walking hall with PT/nurse
|
will be recorded daily as yes/no
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yar Yeap, MD, Indiana University Hospital
Publications and helpful links
General Publications
- Ozyuvaci E, Altan A, Karadeniz T, Topsakal M, Besisik A, Yucel M. General anesthesia versus epidural and general anesthesia in radical cystectomy. Urol Int. 2005;74(1):62-7. doi: 10.1159/000082712.
- Butterworth Iv, John F., David C. Mackey, and John D. Wasnick.
- de Boer, H. D., O. Detriche, and P. Forget.
- Guo, Q., R. Li, L. Wang, D. Zhang, and Y. Ma.
- Hou, X., Z. Luo, H. Wang, Y. Zhan, L. Yang, and L. Li.
- Kalogera, E., J. N. Bakkum-Gamez, A. L. Weaver, J. P. Moriarty, B. J. Borah, C. L. Langstraat, C. J. Jankowski, et al.
- Ladjevic N, Likic-Ladjevic I, Dzamic Z, Acimovic M, Dragicevic D, Durutovic O. Combined general and epidural anaesthesia versus general anaesthesia for radical cystectomy. Acta Chir Iugosl. 2007;54(4):89-91. doi: 10.2298/aci0704089l.
- Mazul-Sunko B, Gilja I, Jelisavac M, Kozul I, Troha D, Osmancevic N, El-Saleh A, Markic A, Kovacevic M, Bokarica P. Thoracic epidural analgesia for radical cystectomy improves bowel function even in traditional perioperative care: a retrospective study in eighty-five patients. Acta Clin Croat. 2014 Sep;53(3):319-25.
- ozek, J. J., M. De Ruyter, and T. W. Khan.
- Sun, J. X., K. Y. Bai, Y. F. Liu, G. Du, Z. H. Fu, H. Zhang, J. H. Yang, et al.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Postoperative Complications
- Pain
- Neurologic Manifestations
- Pain, Postoperative
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics
- Analgesics, Opioid
- Narcotics
- Anesthetics, Local
- Bupivacaine
- Hydromorphone
Other Study ID Numbers
- 1905006917
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystectomy
-
William Beaumont HospitalsCompleted
-
TengionCompletedCystectomyUnited States
-
Mansoura UniversityCompleted
-
Hadassah Medical OrganizationUnknownHemodynamic Monitoring | Radical Cystectomy | Perioperative ComplicationsIsrael
-
University Hospitals, LeicesterCompletedOpen Radical CystectomyUnited Kingdom
-
University of California, IrvineCompleted
-
Lawson Health Research InstituteTerminatedHysterectomy | Regional Anesthesia | CystectomyCanada
-
Mansoura UniversityCompleted
-
Regina Elena Cancer InstituteIntuitive SurgicalCompletedRobotic Surgical Procedures | Cystectomy | Surgical StaplersItaly
-
Yonsei UniversityRecruitingPatients Undergoing Transurethral Prostate or Cystectomy Under Spinal AnesthesiaKorea, Republic of
Clinical Trials on epidural bupivacaine 0.05%
-
University of Texas Southwestern Medical CenterCompletedPregnancyUnited States
-
Benaroya Research InstituteCompleted
-
National Cancer Institute, EgyptCompletedPain, PostoperativeEgypt
-
Weill Medical College of Cornell UniversityNew York Presbyterian HospitalCompleted
-
University of ManitobaRecruitingPain, Postoperative | Liver Neoplasms | HepatectomyCanada
-
CHU de Quebec-Universite LavalCompletedProgrammed Intermittent Bolus Versus Continuous Infusion for Epidural Analgesia in Abdominal SurgeryPain, Postoperative | Analgesia, EpiduralCanada
-
MemorialCareUnknown
-
University of Sao Paulo General HospitalCompletedFetal Bradycardia | Hypertonic Uterine | CatecholaminesBrazil
-
Northwestern UniversityCompletedPregnancy | Labor PainUnited States